Key statistics
On Friday, Autolus Therapeutics PLC (AUTL:NSQ) closed at 3.98, 90.43% above the 52 week low of 2.09 set on Oct 04, 2023.
52-week range
Open | 3.92 |
---|---|
High | 3.99 |
Low | 3.84 |
Bid | 3.80 |
Offer | 4.50 |
Previous close | 3.90 |
Average volume | 740.44k |
---|---|
Shares outstanding | 266.09m |
Free float | 8.82m |
P/E (TTM) | -- |
Market cap | 1.06bn USD |
EPS (TTM) | -1.16 USD |
Data delayed at least 15 minutes, as of Oct 04 2024 21:00 BST.
More ▼
Announcements
- Autolus Therapeutics announces appointment of Matthias Will, M.D. as Chief Development Officer
- Autolus Therapeutics Presents Clinical Data Update at the Society of Hematologic Oncology (SOHO) Annual Meeting 2024
- Autolus Therapeutics Reports Second Quarter 2024 Financial Results and Business Updates
- Autolus Therapeutics to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
- Autolus Therapeutics to Present Three Clinical Data Updates on obecabtagene autoleucel (obe-cel) in relapsed/refractory (r/r) B-Cell acute lymphoblastic leukemia (ALL) patients at the 2024 European Hematology Association (EHA) Congress
- Autolus Therapeutics presents longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL in an oral presentation at ASCO
- Autolus Therapeutics Reports First Quarter 2024 Financial Results and Business Updates
- Autolus Therapeutics Announces Delay to its First Quarter 2024 Earnings Release and Conference Call
- Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCO
- Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024
More ▼